Market Forecasts and Industry Analysis Pneumonia Therapeutics Market Analysis By Product | Page 2

are 12 drugs under investigation in phase III trials, 4 drugs under phase II, and 3 drugs under phase I
trial.
The aforementioned factors exemplify the consistent efforts being made by the market players. For
instance, Omadacycline, a tetracycline under phase III clinical trial, developed by Paratek
Pharmaceuticals is being investigated for use in the treatment of ventilator-associated and
community-acquired bacterial pneumonia.
Request a Sample Copy of This Report @
https://www.radiantinsights.com/research/pneumonia-therapeutics-
market/request-sample
Further key findings from the report suggest:
• Vaccines accounted for the largest share in the product segment in 2016. This can be
attributed to their high efficacy and growing inclination of patients toward preventive
measures
• They are also expected to grow at a lucrative rate owing to the recommendation by
WHO for their inclusion in national immunization programs
• Drugs are expected to witness moderate growth rate throughout the forecast period.
This is believed to be a result of the infiltration of generic drugs that are more cost-
efficient.
• North America accounted fora substantial share in the market owing toincreasing
number of supportive government initiatives and high awareness levels amongst the
end-users
• Asia Pacific is expected to witness exponential CAGR during the forecast period owing
to its high disease burden and continual infrastructural upgradation of research &
manufacturing facilities in the region
• High competition has been observed in the market, where major players adopt
strategies such as new product development, collaborations,and strategic agreements
to gain market share
See More Reports of This Category by Radiant Insights @
https://www.radiantinsights.com/catalog/pharmaceutical
Follow Us: